NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Diagnostic Hybrids' respiratory viral identification kit for use in the US, the company said Tuesday.
Diagnostic Hybrids, which is based in Athens, Ohio, said that the FDA has cleared its D3 Fastpoint L-DFA RSV/MPV Identification kit.
The kit allows for the identification of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in less than 25 minutes.
The kit uses fluorescent labeling technologies and an L-DFA technology that enables simultaneous identification of two respiratory viruses in a single slide.
RSV is the leading cause of infectious viral disease in infants and children under one year old, and hMPV causes diseases in all age groups, and it particularly strikes children and elderly adults, the company said.
Earlier this week, diagnostic firm Quidel said that it had agreed to acquire Diagnostic Hybrids for $130 million.